通过皮肤进行的耳膜迷走神经刺激改善了帕金森病中的步态和皮质活动:一项试点随机研究
Heng Zhang1, Xing-Yue Cao1, Li-Na Wang1
1Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
CNS neuroscience & therapeutics
|June 13, 2023
概括
通过皮肤进行耳道迷走神经刺激 (taVNS) 改善了帕金森病患者的步态. 这种非侵入性疗法增强了步行速度和步伐长度,这表明它可以帮助重塑感觉运动一体化.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 康复医学 康复医学 康复医学
背景情况:
- 帕金森病 (PD) 的特点是步行障碍,影响移动性和生活质量.
- 在PD患者的步行不稳定性包括在行走时运动范围不足.
- 了解导致步态障碍的神经机制对于开发有效治疗方法至关重要.
研究的目的:
- 为了研究20Hz的通过皮肤的耳道迷走神经刺激 (taVNS) 对帕金森病 (PD) 患者的步行障碍的影响.
- 探索taVNS对PD行走的影响的潜在神经机制.
- 为了比较PD患者中活跃taVNS与虚假taVNS的疗效.
主要方法:
- 一个随机,双盲,假控制的试验,涉及22名PD患者和14名健康对照 (HC).
- 患有PD的患者每天两次接受活性或虚拟taVNS,持续一周.
- 功能近红外光谱学 (fNIRS) 在所有受试者中测量了行走期间的皮质激活.
主要成果:
- 积极的taVNS显著改善了步行特征,包括步长,步速,步长和步长变化,与假的taVNS相比.
- 在统一帕金森病评级尺度III,定时上升和上升,蒂内蒂平衡和步行得分中没有发现显著差异.
- 患有PD的患者在行走时在感觉运动区域呈现出更高的氧血球变化;taVNS在左主体感官皮层降低了血液动力学反应.
结论:
- 通过皮肤进行耳道迷走神经刺激 (taVNS) 可以有效地缓解帕金森病患者的步行障碍.
- 在患有PD的个体中,taVNS疗法显示出重塑感官运动整合的潜力.
- 这种非侵入性神经调节技术为PD相关的行走障碍提供了有前途的治疗方法.
相关概念视频
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Parkinson's Disease: Overview
611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611


